The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
本发明涉及式 I 的金属-β-内酰胺酶抑制剂化合物:及其药学上可接受的盐,其中 Z、RA、X1、X2 和 R1 如本文所定义。本发明还涉及组合物,其包含本发明的金属-β-内酰胺酶抑制剂化合物或其药学上可接受的盐,以及药学上可接受的载体,可选择与β-内酰胺抗生素和/或β-内酰胺酶抑制剂结合使用。本发明进一步涉及治疗细菌感染的方法,包括向患者施用治疗有效量的本发明化合物,与治疗有效量的一种或多种β-内酰胺类抗生素联合使用,也可选择与一种或多种β-内酰胺酶抑制剂化合物联合使用。本发明的化合物在本文所述的克服抗生素耐药性的方法中是有用的。
3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:EP3313832B1
公开(公告)日:2021-02-24
METALLO-BETA-LACTAMASE INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:US20180244656A1
公开(公告)日:2018-08-30
The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R
A
, X
1
, X
2
and R
1
are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
[EN] SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY<br/>[FR] COMPOSÉS DE SULFONAMIDE AYANT UNE ACTIVITÉ INHIBITRICE DE TNAP
申请人:DAIICHI SANKYO CO LTD
公开号:WO2018119444A1
公开(公告)日:2018-06-28
The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.